(Q43675571)

25 November 2017

title

Guidelines for the drug treatment of rheumatoid arthritis (English)

1 reference

Geraldo da Rocha Castelar Pinheiro

25 November 2017

1 reference

13

1 reference

Wanderley Marques Bernardo

25 November 2017

12

object named as

Wanderley Marques Bernardo

1 reference

25 November 2017

author name string

Licia Maria Henrique da Mota

1

1 reference

25 November 2017

Bóris Afonso Cruz

2

1 reference

25 November 2017

Claiton Viegas Brenol

3

1 reference

25 November 2017

Ivânio Alves Pereira

4

1 reference

25 November 2017

Lucila Stange Rezende-Fronza

5

1 reference

25 November 2017

Manoel Barros Bertolo

6

1 reference

25 November 2017

Max Vitor Carioca Freitas

7

1 reference

25 November 2017

Nilzio Antônio da Silva

8

1 reference

25 November 2017

Paulo Louzada-Junior

9

1 reference

25 November 2017

Rina Dalva Neubarth Giorgi

10

1 reference

25 November 2017

Rodrigo Aires Corrêa Lima

11

1 reference

25 November 2017

Sociedade Brasileira de Reumatologia

14

1 reference

25 November 2017

publication date

1 April 2013

1 reference

Revista Brasileira de reumatologia

25 November 2017

published in

1 reference

25 November 2017

volume

53

1 reference

25 November 2017

issue

2

1 reference

25 November 2017

page(s)

158-183

1 reference

Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Indirect costs of rheumatoid arthritis in Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

State-of-the-art: rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Recent advances in the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Long-term effects of therapeutic education for patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Effects of an educational-behavioral joint protection program on people with moderate to severe rheumatoid arthritis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Effectiveness of individual resource-oriented joint protection education in people with rheumatoid arthritis. A randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Abatacept for rheumatoid arthritis: a Cochrane systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Evaluation of an inter-professional educational intervention to improve the use of arthritis best practices in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

The comparative safety of analgesics in older adults with arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undiffere

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Guidelines for the management of rheumatoid arthritis: 2002 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Use of glucocorticoids in rheumatoid arthritis - pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Clinical pharmacokinetics of leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Treating rheumatoid arthritis to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in t

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Contemporary treatment principles for early rheumatoid arthritis: a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Tocilizumab for rheumatoid arthritis: a Cochrane systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Predictors for remission in rheumatoid arthritis patients: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

A double-blind comparison of parenteral methotrexate and parenteral gold in the treatment of early erosive rheumatoid arthritis: An interim report on 102 patients after 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial--an Indian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, rad

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Management of rheumatoid arthritis: summary of NICE guidance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: Results of the METGO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0482-50042013000200004

10.1590/S0482-50042013000200004

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

25 November 2017

1043812323

0 references

1 reference